{"id":"https://openalex.org/W2276310429","doi":"https://doi.org/10.1182/blood.v122.21.677.677","title":"Preliminary Safety and Efficacy Of IPI-145, a Potent Inhibitor Of Phosphoinositide-3-Kinase-\u03b4,\u03b3, In Patients With Chronic Lymphocytic Leukemia","display_name":"Preliminary Safety and Efficacy Of IPI-145, a Potent Inhibitor Of Phosphoinositide-3-Kinase-\u03b4,\u03b3, In Patients With Chronic Lymphocytic Leukemia","publication_year":2013,"publication_date":"2013-11-15","ids":{"openalex":"https://openalex.org/W2276310429","doi":"https://doi.org/10.1182/blood.v122.21.677.677","mag":"2276310429"},"language":"en","primary_location":{"id":"doi:10.1182/blood.v122.21.677.677","doi":"https://doi.org/10.1182/blood.v122.21.677.677","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood.v122.21.677.677","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5000959540","display_name":"Ian W. Flinn","orcid":"https://orcid.org/0000-0001-6724-290X","observed_orcids":["https://orcid.org/0000-0001-6724-290X"]},"institutions":[{"id":"https://openalex.org/I4210100810","display_name":"Sarah Cannon","ror":"https://ror.org/014t21j89","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210100810"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Ian Flinn","raw_affiliation_strings":["Sarah Cannon Research Institute, Nashville, TN, USA,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Sarah Cannon Research Institute, Nashville, TN, USA,","institution_ids":["https://openalex.org/I4210100810"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5005718112","display_name":"Manish R. Patel","orcid":"https://orcid.org/0000-0001-6836-2364","observed_orcids":["https://orcid.org/0000-0001-6836-2364"]},"institutions":[],"countries":[],"is_corresponding":true,"raw_author_name":"Manish Patel","raw_affiliation_strings":["Florida Cancer Specialists, Sarasota, FL, USA,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Florida Cancer Specialists, Sarasota, FL, USA,","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5069054551","display_name":"Brad S. Kahl","orcid":"https://orcid.org/0000-0003-0459-6609","observed_orcids":["https://orcid.org/0000-0003-0459-6609"]},"institutions":[{"id":"https://openalex.org/I135310074","display_name":"University of Wisconsin\u2013Madison","ror":"https://ror.org/01y2jtd41","country_code":"US","type":"education","lineage":["https://openalex.org/I135310074"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Brad S. Kahl","raw_affiliation_strings":["Dept of Medicine, Section of Hematology and Oncology, University of Wisconsin School of Medicine, Madison, WI, USA,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dept of Medicine, Section of Hematology and Oncology, University of Wisconsin School of Medicine, Madison, WI, USA,","institution_ids":["https://openalex.org/I135310074"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5069406522","display_name":"Steven Michael Horwitz","orcid":"https://orcid.org/0000-0002-6399-2006","observed_orcids":["https://orcid.org/0000-0002-6399-2006"]},"institutions":[{"id":"https://openalex.org/I1334819555","display_name":"Memorial Sloan Kettering Cancer Center","ror":"https://ror.org/02yrq0923","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1334819555"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Steven M. Horwitz","raw_affiliation_strings":["Lymphoma Service, Memorial Sloan-Kettering Cancer Center, New York, NY, USA,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Lymphoma Service, Memorial Sloan-Kettering Cancer Center, New York, NY, USA,","institution_ids":["https://openalex.org/I1334819555"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5048583088","display_name":"Francine M. Foss","orcid":"https://orcid.org/0000-0001-7843-3162","observed_orcids":["https://orcid.org/0000-0001-7843-3162"]},"institutions":[{"id":"https://openalex.org/I2802730090","display_name":"Yale Cancer Center","ror":"https://ror.org/03j7sze86","country_code":"US","type":"facility","lineage":["https://openalex.org/I2802730090","https://openalex.org/I4210117499","https://openalex.org/I4210165192"]},{"id":"https://openalex.org/I32971472","display_name":"Yale University","ror":"https://ror.org/03v76x132","country_code":"US","type":"education","lineage":["https://openalex.org/I32971472"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Francine M. Foss","raw_affiliation_strings":["Yale University Cancer Center, New Haven, CT, USA,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Yale University Cancer Center, New Haven, CT, USA,","institution_ids":["https://openalex.org/I2802730090","https://openalex.org/I32971472"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5037784199","display_name":"Yasuhiro Oki","orcid":"https://orcid.org/0000-0003-3038-4298","observed_orcids":["https://orcid.org/0000-0003-3038-4298"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Yasuhiro Oki","raw_affiliation_strings":["MD Anderson Cancer Center, Houston, TX, USA,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"MD Anderson Cancer Center, Houston, TX, USA,","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5041950455","display_name":"Pierluigi Porcu","orcid":"https://orcid.org/0000-0002-8056-023X","observed_orcids":["https://orcid.org/0000-0002-8056-023X"]},"institutions":[{"id":"https://openalex.org/I2802841970","display_name":"The Ohio State University Wexner Medical Center","ror":"https://ror.org/00c01js51","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I2802841970"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Pierluigi Porcu","raw_affiliation_strings":["The Ohio State University Wexner Medical Center, Columbus, OH, USA,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"The Ohio State University Wexner Medical Center, Columbus, OH, USA,","institution_ids":["https://openalex.org/I2802841970"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5112877054","display_name":"Jennifer Sweeney","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210108457","display_name":"Infinity Pharmaceuticals (United States)","ror":"https://ror.org/01sfsq511","country_code":"US","type":"company","lineage":["https://openalex.org/I4210108457"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jennifer Sweeney","raw_affiliation_strings":["Infinity Pharmaceuticals, Inc., Cambridge, MA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Infinity Pharmaceuticals, Inc., Cambridge, MA, USA","institution_ids":["https://openalex.org/I4210108457"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5009763835","display_name":"Kerstin R. Allen","orcid":"https://orcid.org/0009-0004-9286-6158","observed_orcids":["https://orcid.org/0009-0004-9286-6158"]},"institutions":[{"id":"https://openalex.org/I4210108457","display_name":"Infinity Pharmaceuticals (United States)","ror":"https://ror.org/01sfsq511","country_code":"US","type":"company","lineage":["https://openalex.org/I4210108457"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Kerstin Allen","raw_affiliation_strings":["Infinity Pharmaceuticals, Inc., Cambridge, MA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Infinity Pharmaceuticals, Inc., Cambridge, MA, USA","institution_ids":["https://openalex.org/I4210108457"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Kerrie Faia","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210108457","display_name":"Infinity Pharmaceuticals (United States)","ror":"https://ror.org/01sfsq511","country_code":"US","type":"company","lineage":["https://openalex.org/I4210108457"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Kerrie Faia","raw_affiliation_strings":["Infinity Pharmaceuticals, Inc., Cambridge, MA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Infinity Pharmaceuticals, Inc., Cambridge, MA, USA","institution_ids":["https://openalex.org/I4210108457"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5111794967","display_name":"Patricia W. Harris","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210108457","display_name":"Infinity Pharmaceuticals (United States)","ror":"https://ror.org/01sfsq511","country_code":"US","type":"company","lineage":["https://openalex.org/I4210108457"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Patricia Harris","raw_affiliation_strings":["Infinity Pharmaceuticals, Inc., Cambridge, MA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Infinity Pharmaceuticals, Inc., Cambridge, MA, USA","institution_ids":["https://openalex.org/I4210108457"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5075277609","display_name":"Joi Dunbar","orcid":"https://orcid.org/0009-0004-7663-1535","observed_orcids":["https://orcid.org/0009-0004-7663-1535"]},"institutions":[{"id":"https://openalex.org/I4210108457","display_name":"Infinity Pharmaceuticals (United States)","ror":"https://ror.org/01sfsq511","country_code":"US","type":"company","lineage":["https://openalex.org/I4210108457"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Joi Dunbar","raw_affiliation_strings":["Infinity Pharmaceuticals, Inc., Cambridge, MA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Infinity Pharmaceuticals, Inc., Cambridge, MA, USA","institution_ids":["https://openalex.org/I4210108457"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5028575353","display_name":"Howard Marvin Stern","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210108457","display_name":"Infinity Pharmaceuticals (United States)","ror":"https://ror.org/01sfsq511","country_code":"US","type":"company","lineage":["https://openalex.org/I4210108457"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Howard M. Stern","raw_affiliation_strings":["Infinity Pharmaceuticals, Inc., Cambridge, MA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Infinity Pharmaceuticals, Inc., Cambridge, MA, USA","institution_ids":["https://openalex.org/I4210108457"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5066471470","display_name":"Patrick Francis Kelly","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210108457","display_name":"Infinity Pharmaceuticals (United States)","ror":"https://ror.org/01sfsq511","country_code":"US","type":"company","lineage":["https://openalex.org/I4210108457"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Patrick Kelly","raw_affiliation_strings":["Infinity Pharmaceuticals, Inc., Cambridge, MA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Infinity Pharmaceuticals, Inc., Cambridge, MA, USA","institution_ids":["https://openalex.org/I4210108457"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5006104041","display_name":"Susan Mary O'Brien","orcid":"https://orcid.org/0000-0002-2481-7504","observed_orcids":["https://orcid.org/0000-0002-2481-7504"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Susan O'Brien","raw_affiliation_strings":["MD Anderson Cancer Center, Houston, TX, USA,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"MD Anderson Cancer Center, Houston, TX, USA,","institution_ids":["https://openalex.org/I1343551460"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":8,"corresponding_author_ids":["https://openalex.org/A5005718112","https://openalex.org/A5028575353","https://openalex.org/A5075277609","https://openalex.org/A5111794967"],"corresponding_institution_ids":["https://openalex.org/I4210108457"],"apc_list":{"value":5500,"currency":"USD","value_usd":5500},"apc_paid":null,"fwci":4.0964,"has_fulltext":false,"cited_by_count":28,"citation_normalized_percentile":{"value":0.94989092,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":88,"max":100},"biblio":{"volume":"122","issue":"21","first_page":"677","last_page":"677"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11157","display_name":"Chronic Lymphocytic Leukemia Research","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2716","display_name":"Genetics"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11157","display_name":"Chronic Lymphocytic Leukemia Research","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2716","display_name":"Genetics"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10185","display_name":"Lymphoma Diagnosis and Treatment","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2734","display_name":"Pathology and Forensic Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10950","display_name":"Acute Lymphoblastic Leukemia research","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2739","display_name":"Public Health, Environmental and Occupational Health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/idelalisib","display_name":"idelalisib","score":0.7070000171661377},{"id":"https://openalex.org/keywords/pi3kdelta-inhibitor","display_name":"PI3K\u03b4 inhibitor","score":0.6800000071525574},{"id":"https://openalex.org/keywords/chronic-lymphocytic-leukemia","display_name":"chronic lymphocytic leukemia","score":0.9900000095367432},{"id":"https://openalex.org/keywords/relapsed-refractory-cll","display_name":"relapsed/refractory CLL","score":0.9589999914169312},{"id":"https://openalex.org/keywords/maximum-tolerated-dose","display_name":"maximum tolerated dose","score":0.6990000009536743},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.7210000157356262},{"id":"https://openalex.org/keywords/pharmacodynamics","display_name":"pharmacodynamics","score":0.9729999899864197},{"id":"https://openalex.org/keywords/safety","display_name":"safety","score":0.4440000057220459},{"id":"https://openalex.org/keywords/efficacy","display_name":"efficacy","score":0.6869999766349792},{"id":"https://openalex.org/keywords/oral-kinase-inhibitor","display_name":"oral kinase inhibitor","score":0.47099998593330383},{"id":"https://openalex.org/keywords/dose-escalation","display_name":"dose escalation","score":0.6439999938011169},{"id":"https://openalex.org/keywords/pancytopenia","display_name":"pancytopenia","score":0.7839999794960022}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.7908655405044556},{"id":"https://openalex.org/C2777938653","wikidata":"https://www.wikidata.org/wiki/Q1088156","display_name":"Chronic lymphocytic leukemia","level":3,"score":0.6166502237319946},{"id":"https://openalex.org/C2779260929","wikidata":"https://www.wikidata.org/wiki/Q5908266","display_name":"Idelalisib","level":5,"score":0.5615684390068054},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5192137360572815},{"id":"https://openalex.org/C111113717","wikidata":"https://www.wikidata.org/wiki/Q725307","display_name":"Pharmacodynamics","level":3,"score":0.5068581700325012},{"id":"https://openalex.org/C112705442","wikidata":"https://www.wikidata.org/wiki/Q323936","display_name":"Pharmacokinetics","level":2,"score":0.4842910170555115},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.45092862844467163},{"id":"https://openalex.org/C2779382419","wikidata":"https://www.wikidata.org/wiki/Q1757427","display_name":"Pancytopenia","level":3,"score":0.4285885989665985},{"id":"https://openalex.org/C2778461978","wikidata":"https://www.wikidata.org/wiki/Q29496","display_name":"Leukemia","level":2,"score":0.42600560188293457},{"id":"https://openalex.org/C142424586","wikidata":"https://www.wikidata.org/wiki/Q7307572","display_name":"Refractory (planetary science)","level":2,"score":0.41250288486480713},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.4060613214969635},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.32333630323410034},{"id":"https://openalex.org/C2779878957","wikidata":"https://www.wikidata.org/wiki/Q5984881","display_name":"Ibrutinib","level":4,"score":0.2548685073852539},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.07726499438285828},{"id":"https://openalex.org/C2780007613","wikidata":"https://www.wikidata.org/wiki/Q546523","display_name":"Bone marrow","level":2,"score":0.07377928495407104},{"id":"https://openalex.org/C87355193","wikidata":"https://www.wikidata.org/wiki/Q411","display_name":"Astrobiology","level":1,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1182/blood.v122.21.677.677","doi":"https://doi.org/10.1182/blood.v122.21.677.677","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood.v122.21.677.677","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":1.0,"display_name":"Good health and well-being"}],"study_designs":[{"id":"https://openalex.org/study-designs/clinical-trial","display_name":"Clinical Trial"}],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2603765845","https://openalex.org/W2592558314","https://openalex.org/W2574515093","https://openalex.org/W4242290472","https://openalex.org/W4254354035","https://openalex.org/W2562606704","https://openalex.org/W2597426544","https://openalex.org/W2551966143","https://openalex.org/W2341725288","https://openalex.org/W2242208648"],"abstract_inverted_index":{"Abstract":[0],"Introduction":[1],"IPI-145":[2,101,295,447,462,681,692],"is":[3,35,44,82,198,333,482,544,568,649],"an":[4,590,614,664,779],"oral,":[5,615],"potent":[6,616],"PI3K-\u03b4,\u03b3":[7,617],"inhibitor":[8],"currently":[9],"in":[10,103,115,188,338,359,382,401,432,441,454,472,497,509,515,532,592,628,654,670],"development":[11],"for":[12,558,595,663],"the":[13,30,68,86,116,128,150,231,485,559,577,634],"treatment":[14,521],"of":[15,29,56,98,108,161,166,193,217,246,280,302,321,342,429,446,461,494,517,540,576,585,636,782],"hematologic":[16],"(heme)":[17],"malignancies.":[18],"Biochemical":[19],"/cellular":[20],"and":[21,32,52,76,96,140,146,164,238,250,267,306,311,325,344,373,436,439,471,553,574,622,641,657,686,696],"whole":[22],"blood":[23],"assays":[24],"indicate":[25],"that":[26,645],"differential":[27],"inhibition":[28,165,428],"PI3K-\u03b4":[31,162],"PI3K-\u03b3":[33,167],"isoforms":[34],"possible.":[36],"An":[37,191],"ongoing":[38,139,200],"Phase":[39,79,667],"1":[40,80,547,554,572],"study":[41,81],"(ClinicalTrials.gov":[42],"NCT01476657)":[43],"evaluating":[45],"patients":[46],"(pts)":[47],"with":[48,58,110,122,134,177,227,241,252,417,474,484,501,546,604,630],"advanced":[49],"heme":[50,111],"malignancies":[51,112],"includes":[53],"a":[54,242,253,650],"subset":[55],"pts":[57,71,109,137,176,197,221,226,261,281,293,313,360,404,457,473,518,534,562,580,597,603,629,678,689],"relapsed/refractory":[59],"(R/R)":[60],"chronic":[61],"lymphocytic":[62],"leukemia":[63],"(CLL).":[64],"Preliminary":[65],"results":[66],"from":[67,272,464,675],"R/R":[69,135,228,232,259,291,455,475,602,631,655,671,687],"CLL":[70,136,175,196,205,233,260,292,456,632,677,688],"are":[72,138,186,207],"reported":[73],"here.":[74],"Methods":[75],"Patients":[77],"This":[78],"designed":[83],"to":[84,182,467,489,535,589],"evaluate":[85],"safety,":[87],"maximum":[88,418],"tolerated":[89,621],"dose":[90,117,152,335,653,659],"(MTD),":[91],"pharmacokinetics":[92],"(PK),":[93],"pharmacodynamics":[94],"(PD),":[95],"activity":[97,450,627,643],"orally":[99],"administered":[100],"BID":[102,125,144,298,317,425,470,567,648,685,699],"28-day":[104],"cycles.":[105,522],"Sequential":[106],"cohorts":[107,132],"were":[113,236,269,353,395],"enrolled":[114],"escalation":[118],"(DE)":[119],"phase":[120],"(completed),":[121],"75":[123,142,315,414,468,697],"mg":[124,143,148,203,297,316,364,415,424,466,469,566,647,684,695,698],"identified":[126],"as":[127],"MTD.":[129],"Two":[130],"expansion":[131],"(ECs)":[133],"examine":[141],"(MTD)":[145],"25":[147,202,363,646,683,694],"BID;":[149],"latter":[151],"was":[153],"selected":[154,662],"based":[155,209,426],"on":[156,210,309,328,427,527,600,778],"PK/PD":[157,406,640],"showing":[158],"complete":[159],"suppression":[160],"(>IC90)":[163],"(\u2265":[168],"IC50)":[169],"at":[170,201,421,458,564,682,693],"steady":[171],"state.":[172],"Of":[173],"note,":[174],"pancytopenia":[178],"and/or":[179,287,397],"prior":[180,264],"exposure":[181,409],"PI3K-":[183],"or":[184,340,784],"BTK-inhibitors":[185],"allowed":[187],"these":[189],"ECs.":[190],"EC":[192],"high-risk,":[194],"treatment-na\u00efve":[195,676],"also":[199],"BID.":[204],"responses":[206,506],"evaluated":[208],"modified":[211],"IWCLL":[212],"(2008)":[213],"criteria.":[214],"Results":[215],"As":[216],"July":[218],"2013,":[219],"155":[220],"have":[222],"enrolled,":[223],"including":[224,571],"44":[225],"CLL.":[229,672],"Within":[230],"pts,":[234],"77%":[235],"male":[237],"23%":[239],"female,":[240],"median":[243,486],"(range)":[244],"age":[245],"67":[247],"years":[248],"(51-82),":[249],"93%":[251],"baseline":[254,490],"ECOG":[255],"\u22641.":[256],"Thirty-three":[257],"(75%)":[258],"had":[262,284,609],"\u22653":[263],"systemic":[265],"therapies":[266],"62%":[268],"<6":[270],"months":[271],"their":[273],"most":[274,347,392],"recent":[275],"therapy.":[276],"Forty-four":[277],"percent":[278],"(44%)":[279],"tested":[282],"(n=32)":[283],"TP53":[285],"mutation":[286],"17p":[288],"deletion.":[289],"Twenty-three":[290],"received":[294,314,680,691],"\u226425":[296,565],"(median":[299,318,537],"[range]":[300,319,538],"number":[301,320,539],"cycles":[303,322,445,493,541],"5.6":[304],"[1-21]":[305],"43%":[307],"remain":[308,327,599],"study)":[310],"21":[312],"3.6":[323],"[1\u20136]":[324],"76%":[326],"study).":[329],"To":[330],"date,":[331],"there":[332],"no":[334,386,502],"related":[336],"increase":[337,380,591],"frequency":[339],"severity":[341],"AEs":[343,352],"SAEs.":[345],"The":[346,391,556,639],"common":[348],"\u2265":[349],"Grade":[350,377,387],"3":[351,378,668],"transient":[354],"neutropenia":[355,370],"(n=9":[356],"[20%];":[357],"all":[358,459],"receiving":[361],"\u2264":[362],"BID),":[365],"anemia":[366],"(n=4":[367],"[9%]),":[368],"febrile":[369],"(n=3":[371,375],"[7%]),":[372],"pneumonitis":[374],"[7%]).":[376],"ALT/AST":[379],"occurred":[381,514],"2":[383,444,520],"(5%)":[384],"pts;":[385],"4":[388],"elevations":[389],"occurred.":[390],"frequently-occurring":[393],"SAEs":[394],"respiratory":[396],"infectious":[398],"events":[399],"occurring":[400],"11":[402],"(25%)":[403],"total.":[405],"data":[407,674],"demonstrate":[408],"(AUC)":[410],"increases":[411],"proportionally":[412],"through":[413],"BID,":[416],"PD":[419],"effects":[420],"doses":[422,460,637],"\u226525":[423],"pAKT,":[430],"reductions":[431],"serum":[433],"cytokines,":[434],"chemokines":[435],"matrix":[437],"metalloproteinases":[438],"reduction":[440,508],"adenopathy":[442,498,510],"after":[443,519],"treatment.":[448,495],"Clinical":[449],"has":[451,623,660],"been":[452,661],"observed":[453],"studied":[463],"8":[465,578],"high-risk":[476,605],"disease":[477,606],"(TP53":[478,607],"mut/17pdel).":[479],"Treatment-related":[480],"lymphocytosis":[481,586],"rapid,":[483],"ALC":[487],"return":[488],"within":[491],"6":[492],"Reduction":[496],"occurs":[499],"early":[500],"apparent":[503],"dose-dependence.":[504],"Nodal":[505],"(>50%":[507],"by":[511],"CT":[512],"assessment)":[513],"79%":[516],"Best":[523],"overall":[524],"response":[525],"(based":[526],"investigator":[528],"assessment":[529],"per":[530],"IWCLL)":[531],"evaluable":[533,561],"date":[536],"5.1":[542],"[1-21.1])":[543],"52%,":[545],"CR,":[548],"15":[549],"PR,":[550],"14":[551],"SD":[552,579,596],"PD.":[555],"ORR":[557,594],"19":[560],"treated":[563],"53%":[569],"(10/19;":[570],"CR)":[573],"7":[575],"achieving":[581],"nodal":[582],"response.":[583],"Resolution":[584],"may":[587],"lead":[588],"best":[593],"who":[598,679,690],"study.":[601],"mut/17pdel)":[608],"similar":[610],"ORR.":[611],"Conclusions":[612],"IPI-145,":[613],"inhibitor,":[618],"appears":[619],"well":[620],"shown":[624],"promising":[625],"clinical":[626,642],"across":[633],"range":[635],"examined.":[638],"suggest":[644],"biologically":[651],"active":[652],"CLL,":[656],"this":[658],"upcoming":[665],"randomized":[666],"trial":[669],"Updated":[673],"will":[700],"be":[701],"presented.":[702],"Disclosures:":[703],"Flinn:":[704],"Infinity":[705,718,757,787],"Pharmaceuticals,":[706,719,724,758,763,788,793,797,801,805,809,813,817,821],"Inc.:":[707,720,725,759,764,789,794,798,802,806,810,814,818,822],"Consultancy,":[708,726],"Research":[709,714,721,727,750,760,765,790,823],"Funding.":[710,722,728,751,761,766,791,824],"Patel:Lilly,":[711],"Medivation:":[712],"Honoraria,":[713],"Funding,":[715],"Speakers":[716],"Bureau;":[717],"Kahl:Infinity":[723],"Horwitz:Celgene,":[729],"Allos,":[730,744],"Seattle":[731,745],"Genetics,":[732,746],"Bristol-Myers":[733],"Squibb,":[734],"Genzyme,":[735],"Kyowa,":[736,747],"Janssen,":[737],"Johnson":[738],"&":[739],"Johnson,":[740],"Millenium:":[741,749,755],"Consultancy;":[742,756],"Celgene,":[743,753],"Infinty,":[748],"Foss:Eisai,":[752],"Spectrum,":[754],"Oki:Infinity":[762],"Porcu:United":[767],"States":[768],"Cutaneous":[769,773],"Lymphoma":[770,774],"Consortium":[771],"(USCLC)":[772],"Foundation":[775],"(CLF):":[776],"Membership":[777],"entity\u2019s":[780],"Board":[781],"Directors":[783],"advisory":[785],"committees;":[786],"Sweeney:Infinity":[792],"Employment.":[795,799,803,807,811,815,819],"Allen:Infinity":[796],"Faia:Infinity":[800],"Harris:Infinity":[804],"Dunbar:Infinity":[808],"Stern:Infinity":[812],"Kelly:Infinity":[816],"O'Brien:Infinity":[820]},"counts_by_year":[{"year":2021,"cited_by_count":1},{"year":2018,"cited_by_count":1},{"year":2017,"cited_by_count":1},{"year":2016,"cited_by_count":5},{"year":2015,"cited_by_count":5},{"year":2014,"cited_by_count":15}],"updated_date":"2026-10-17T09:40:24.721904","created_date":"2016-06-24T00:00:00"}